ArticleJACC. Asia2026
Integrated Use of Late Gadolinium Enhancement and Left Ventricular Global Longitudinal Strain in Hypertrophic Cardiomyopathy.
Article in JACC. Asia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Fibrosis and Myocardial Dysfunction in Hypertrophic Cardiomyopathy: A Sisyphean Association or a Challenge Worth Pursuing?JACC. Asia · 2026Article
- Recent advances in biomarkers for cardiac fibrosis.Frontiers in cardiovascular medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLate gadolinium enhancement (LGE) and left ventricular global longitudinal strain (LV-GLS) are structural and functional left ventricular remodeling markers in hypertrophic cardiomyopathy (HCM).
objectivesThis study investigated the prognostic value of integrating both markers for risk stratification in HCM.
methodsConsecutive patients with HCM who underwent CMR between 2008 and 2020 at 2 tertiary hospitals were retrospectively analyzed. LGE% and LV-GLS were measured, with LV-GLS reported as an absolute value. The primary outcome was cardiovascular (CV) events: CV death, sudden cardiac death-related events, and heart failure hospitalization.
resultsAmong 652 patients with HCM (median age 56 years; 74% [481 of 652] male), median LGE% and LV-GLS were 4.2% and 14.3%, respectively. During the median 7.4-year follow-up (Q1-Q3: 3.4-10.3 years), 59 patients (9.0%) experienced CV events. Higher LGE% and lower LV-GLS were associated with increased CV events (per 1% LGE% increase, adjusted HR [aHR]: 1.04 [95% CI: 1.01-1.06; P = 0.005]; per 1% LV-GLS decrease, aHR: 1.08 [95% CI 1.00-1.15; P = 0.038]). When analyzing the 4 groups stratified according to LGE% and LV-GLS, patients with both high LGE% (>4.2%) and low LV-GLS (<14.3%) had the highest incidence of CV events (aHR: 2.88; 95% CI: 1.21-6.85; P = 0.017). Mediation analysis showed a significant indirect effect of LGE% on CV events through LV-GLS. Sudden cardiac death-related events were most frequent in patients with both high LGE and low LV-GLS.
conclusionsLGE and LV-GLS provide complementary prognostic information in HCM. Patients with both increased LGE and decreased LV-GLS are at particularly high risk, highlighting the value of integrating both biomarkers for risk stratification.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.